RECRUITINGOBSERVATIONAL
A Retrospective Real-World Study Based on RATIONALE-307
Long-Term Efficacy and Safety Analysis of First-Line Tislelizumab in Patients With Advanced Squamous NSCLC: a Retrospective Real-World Study Based on RATIONALE-307
About This Trial
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
Who Should NOT Join This Trial:
- Patients who had a documented death before study completion in the RATIONALE-307 trial
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
Exclusion Criteria:
* Patients who had a documented death before study completion in the RATIONALE-307 trial
Treatments Being Tested
OTHER
No intervention
No intervention
Locations (1)
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China